Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Derek Walsh · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $407,172 — PROJECT SUMMARY Humans have a profound, double-edged relationship with poxviruses. On one hand, the devastating effects of smallpox are unparalleled by any other pathogen in recorded history, and its eradication is a milestone in modern medicine. On the other, poxviruses are now used as highly effec…
ANEEL K. AGGARWAL · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $211,875 — The Flavivirus genus includes mosquito-borne human pathogens, such as dengue virus, yellow fever virus, and the Zika virus (ZIKV), among others. ZIKV's recent spread in Americas and its link to microcephaly in newborn infants and the Guillan-Barré syndrome in adults has invigorated efforts to develo…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $4,527,376 — A key goal of HIV-1 vaccine development is to induce long-lasting broadly neutralizing antibodies (bnAbs) that can inhibit HIV-1 infection. Messenger (m) RNA has emerged as a promising new vaccine modality that can elicit potent immune responses, while avoiding the safety risks and anti-vector immun…
Afamefuna Okoye · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $850,670 — PROJECT SUMMARY Although the advent of combination antiretroviral therapy (cART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV), cART alone cannot eradicate the infection and, therefore, daily treatment must be maintained for life to prevent relapse …
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2020 · $860,928 — PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we propose to leverage three recent discoveries from our groups to generate novel envelope (Env) immunogens that target the V1V2 region of the trimer…
Philip Bradley · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $2,000,000 — Project Summary/Abstract Fred Hutch respectfully requests funds to upgrade the current 523-node, 3328-core high performance computing (HPC) cluster, which was created in 2004 and expanded in 2006, 2010 (S10 funds), 2013, 2015 (S10 funds), and 2018. 456 end of life nodes (1824 cores) will be replaced…
DEBORAH M HINTON · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2020 · $355,031 — Nearly all virulence factors in Bordetella pertussis are activated by a master two-component system, BvgAS, composed of the sensor kinase BvgS and the response regulator BvgA. When BvgS is active, BvgA is phosphorylated (BvgAP), and virulence activated genes are expressed (the Bvg(+) mode). When B…
Jeffrey Cohen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $947,827 — Herpes simplex virus 2 (HSV-2) causes genital herpes and increases the risk of transmission and infection with HIV. Thus a vaccine for HSV-2 would not only reduce the rate of genital herpes, but also might reduce spread of HIV. Several HSV-2 vaccines have been tested in humans for prevention or redu…
BARBARA K FELBER · DIVISION OF BASIC SCIENCES - NCI · 2020 · $1,866,900 — An ideal HIV vaccine should provide protection against all HIV-1 variants. Thus, an important aspect of HIV vaccine development is the selection of immunogens, which has to take into consideration the diversity of the different HIV clades and the identification of the critical epitopes able to induc…
Elizabeth Conner · DIVISION OF BASIC SCIENCES - NCI · 2020 · $1,642,585 — CCR Genomics Core lists over 1040 registered members in its iLab management and scheduling software with 270 research groups of which 192 are from NCI and the remaining 77 from 13 other NIH institutes. These institutes include NIAID, NHGRI, NEI, NINDS, NHLBI, NIAMS, NIDDK, NIMH, NIA, NIAAA, NIDCD, N…
LOUISE C. SHOWE · WISTAR INSTITUTE · 2020 · $205,228 — PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service,…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $942,168 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
GARRY P NOLAN · STANFORD UNIVERSITY · 2020 · $306,812 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
Barney Graham · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $3,038,369 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal changes in influenza viruses (drift) and emergence of new pandemic strains (shift). This study aims to develop new platforms and vaccination strat…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2020 · $686,141 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
SILVIA GRAMA · NANOCOMPOSIX, INC. · 2020 · $300,000 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
FANG LIU · ZYMERON CORPORATION · 2020 · $300,000 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
DAVID MCCORMICK · IIT RESEARCH INSTITUTE · 2020 · $430,361 — PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER…
JULIE AKE · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $22,000,000 — The NIAID Division of AIDS and the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Development Command (MRDC) remain committed to the common objective of developing a safe and effective vaccine for HIV/AIDS. The Agencies recog…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $871,042 — Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages A major goal of HIV-1 vaccine development is to induce broadly neutralizing antibodies (bnAbs). This IPCAVD team has immunogens that can trigger unmutate…